HMGCR and metabolic disease: Song et al. reported that the mTORC1-USP20-HMGCR axis, a post-transcriptional mechanism, participated in the turnover of HMGCR and that the inhibition of USP20 might be beneficial for a variety of metabolic diseases, such as diabetes, hyperlipidemia, and CVD [48].